Skip to main content

Lupus

      Can Antimalarials be Withdrawn in Quiescent Lupus?

      Antimalaria (AM) therapy is a cornerstone to the management of syste

      Dr. John Cush RheumNow

      3 years 2 months ago
      Can Antimalarials be Withdrawn in Quiescent Lupus? Antimalaria (AM) therapy is a cornerstone to the management of systemic lupus erythematosus (SLE), yet a recent study suggests that slowly tapering AM yields a lower rate of SLE flares. https://t.co/dYJy5BOKay https://t.co/pgz694ep2G
      Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superi

      Dr. John Cush RheumNow

      3 years 2 months ago
      Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://t.co/uMY5uPPabA https://t.co/nG2RO6oEJQ
      Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://bit.ly/3RvPzDm
      Antimalaria (AM) therapy is a cornerstone to the management of systemic lupus erythematosus (SLE), yet a recent study suggests that slowly tapering AM yields a lower rate of SLE flares. 
      Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7

      Dr. John Cush RheumNow

      3 years 2 months ago
      Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/wWJhlY5IYW cc: @RichardPAConway : https://t.co/2IAURdfAOB
      Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, speci

      Dr. John Cush RheumNow

      3 years 2 months ago
      Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) #EULAR2022 POS0774. cc: @RichardPAConway https://t.co/cwp6q4kouz
      Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst

      Dr. John Cush RheumNow

      3 years 2 months ago
      Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 #MedTwitter https://t.co/xUkQmwoeni
      Babies! Safety and Outcomes Data on Pregnancies

      #EULAR2022 highlighted several posters on pregnancy, an important subje

      Dr. John Cush RheumNow

      3 years 2 months ago
      Babies! Safety and Outcomes Data on Pregnancies #EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye... https://t.co/piA1zhGyAA https://t.co/Kb68AGZgA1
      Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V

      Dr. John Cush RheumNow

      3 years 2 months ago
      Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V
      Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (O

      Dr. John Cush RheumNow

      3 years 2 months ago
      Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx
      Lupus Research Alliance’s has awarded the Lupus Insight Prize to Akiko Iwasaki, PhD (professor at Yale School of Medic

      Dr. John Cush RheumNow

      3 years 2 months ago
      Lupus Research Alliance’s has awarded the Lupus Insight Prize to Akiko Iwasaki, PhD (professor at Yale School of Medicine) for her research on the pathogenic role of retroviruses in lupus published in Journal of Experimental Medicine https://t.co/xmQjFLk63K https://t.co/68Ezlfk00j
      Does Sunlight Trigger Lupus?

      Whether exposure to ultraviolet (UV) radiation from the sun can cause new-onset systemic l

      Dr. John Cush RheumNow

      3 years 2 months ago
      Does Sunlight Trigger Lupus? Whether exposure to ultraviolet (UV) radiation from the sun can cause new-onset systemic lupus erythematosus (SLE) wasn't settled by data from a large, long-running epidemiologic study, but the trends indicated that it could. https://t.co/IYhPv0dB9Z https://t.co/cza7qGSCbu
      Does Sunlight Trigger Lupus?
      • MedPage Today
      Whether exposure to ultraviolet (UV) radiation from the sun can cause new-onset systemic lupus erythematosus (SLE) wasn't settled by data from a large, long-running epidemiologic study, but the trends indicated that it could.
      ×